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Tim effects of C-type natriuretic peptide (CNP) on the 
hypothnlnmo-pituitary-adrenal system response to 
different stressors was studied. Various doses of CNP 
(0.2, 2, 4 |xg) were injected into the lateral cerebral 
ventricle of freely moving rats 30 min before stress and 
activation of the adrenal was measured by plasma corti-
costerone. CNP did not affect basal corticosterone secre-
tion in the doses applied, but inhibited in a 
dose-dependent manner the increase in plasma corticos-
terone induced by ether stress, electric shock and 
restraint. CNP exerted a more profound inhibitory effect 
on the response to ether stress than on that to electric 
shock or restraint. These results suggest that CNP acts 
centrally and to a different extent on the responses to 
different stresses. NeuroReport 9:2601-2603 © 1998 Rapid 
Science Ltd. 
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Introduction 
Atrial natriuretic peptide (ANP), which is present 
in the brain,1,2 is able to inhibit pituitary [p-]adrenal 
activation.3"10 C-type natriuretic peptide (CNP) can 
also be detected in the brain,"*12 and seems to be the 
most abundant type of natriuretic peptide in the 
central nervous system.13 Since both A N P and C N P 
are members of a family of peptides which share 
homologous sequences in chemical structure, "*14 
involvement of C N P in the control of the pituitary[p-
jadrcnal axis seemed likely. The present experiments 
therefore explored the effect of C N P introduced into 
the lateral cerebral ventricle on basal corticosterone 
secretion, and on the changes induced by three 
types of stress: ether stress, electric foot-shock and 
restraint. 
Materials and Methods 
The animals were kept and handled during the exper-
iments in accordance with the instructions of the 
Albert Szent-Györgyi Medical University Ethical 
Committee for the Protection of Animals. 
Adult male Wistar rats weighing 150-200 g were 
housed 5 per cage on a 12:12 h light:dark cycle 
with access to a standard diet. The rats were handled 
daily for 1 week before the experiment to reduce 
the effects of non-specific stress. In order to allow 
intracercbroventricular (i.e.v.) peptide administration, 
the rats were implanted with a stainless steel cannula 
© Rapid Science Ltd 
introduced into the right cerebral ventricle 1 week 
before the experiment, at coordinates 0.2 mm poste-
rior and 1.7 mm lateral to the bregma, and 3.7 mm 
deep from the dural surface, according to the atlas 
of Pellegrino et it/.15 Surgery was performed under 
pentobarbital (Nembutal 35 mg/kg, ip.) anesthesia. 
Cannulas were secured with dental acrylic cement. 
The rats were allowed a minimum of 5 days to 
recover from the surgery before peptide treatment. 
Rat CNP-22 was purchased from Bachem (Cal, 
USA). All experiments started at 08.00 h. 
Different doses (from 20 ng to 4.0 p.g) of C N P 
dissolved in saline, or saline alone (control animals), 
was injected i.c.v. in a volume of 2 p.1, immobiliza-
tion of the animals being avoided during handling. 
Thirty min after the i.c.v. injection, the animals were 
exposed to different stressors. For ether stress, rats 
were removed from their cages and placed indivi-
dually for 1.5 min in a large closed jar containing 
paper towels saturated with diethyl-ether. Electric 
foot-shock was given to rats placed in a shock-box 
(a wooden box with a stainless steel grid floor). 
Animals were exposed to an unescapable foot-shock 
of 1 mA for 5 s every 15 s for a total of 1 min. 
Restraint involved placing the animals in a plastic 
tube, which was closed at either end with a metal 
plate, for 30 min. 
The animals were sacrificed by decapitation in a 
separate room 30 min after the stress procedures. 
Approximately •'3 ml trunk blood was collected 
into beakers containing 0.2 ml heparin. The plasma 
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corticostcrone level was measured by the fluorescence 
assay described by Zenker and Berstein16 and modi-
fied by Purves and Sirctt.17 At the same time, to verify 
the permeability of the cannulas, methylene blue was 
injected into each decapitated head and the brains 
were dissected. O n l y animals with correctly located 
cannulas were used for evaluation. 
Values are presented as means ± s.e.m. Data were 
evaluated statistically using the A N O V A procedure 
followed by T u k e y ' s post hoc test. A probabil i ty 
level of p < 0.05 was considered to be statistically 
significant. 
Results 
C N P in a dose of 2 p.g or 4 p.g had no significant 
effect on the basal level of plasma corticosterone (Figs 
1-3). Ether stress (Fig. 1), electric shock (Fig. 2) or 
restraint (Fig. 3) all caused an approximately 4-fold 
increase in plasma cort icosterone. C N P caused a 
dose-dependent inhibit ion of ether-stress-induced 
secretion of cor t icosterone (Fig. 1). The effect was 
significant (p < 0.001) even at a dose of 0.02 p-g: the 
corticosterone response was inhibited by 58% by 
0.2 p.g and abolished by 2 p.g C N P (both p < 0.0001) 
so that there was no difference f rom controls 
(p a 0.096 and 0.93, respectively). The effects of C N P 
on the cort icosterone response to electric shock were 
less marked (Fig. 2). T h e 2 p.g dose, which abolished 
the response to ether, decreased the cort icosterone 
response by only 2 4 % [p < 0.005); the 4 p.g dose 
decreased the response by 3 4 % (p < 0.001) but to 
a level still significantly above that in controls 
( p < 0.0001). T h e effects of C N P on the corticos-
terone response to restraint stress were also less 
marked (Fig. 3). O n l y the highest dose of C N P 
(4 p.g) was able to diminish the restraint-induced 
increase in plasma cor t icosterone in a statistically 
significant manner (p < 0.01); the effect of 2 p.g C N P 
was not significant. 
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FIG. 1. The effect of C-type natriuretic peptide on ether stress-
induced plasma corticosterone levels. 0.0002 vs ether; * p -
0.0001 vs ether; p . 0.0001 vs ether. Figures within the bars repre-
sent the number of animals used. 
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FIG. 2. The effect of C-type natriuretic peptide on plasma corti-
costerone levels evoked by electric shock. +p = 0.0046 vs electric 
shock; ' p - 0.0003 vs electric shock. Figures within the bars repre-
sent the number of animals used. 
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FIG. 3. The effect of C-type natriuretic peptide on plasma corti-
costerone levels evoked by restraint. *p = 0.0099 vs restraint. Figures 
within the bars represent the number of animals used. 
Discussion 
T h e chemical similarity between A N P and C N P " ' 1 4 
suggests that they might also share biological activity. 
A N P inhibits A C T H secretion at the pituitary 
level,4-9 and may also inhibit the release of corti-
cot rophin releasing hormone (CRH). 3 ' 1 0 
We have demonstrated that i.e.v. administered 
C N P can decrease the secretion of cort icostcrone 
induced by three different stresses, bu t it is not 
able to affect the basal secretion. This probably 
occurs by a central neuropeptide action of C N P on 
the hypotha lamo-pi tu i ta ry C R H - A C T H axis. This 
hypothesis is supported by the findings of Charles 
et it/.,18 w h o showed i.c.v. administered C N P to 
suppress the adrenocortical response to hypotension 
in the sheep. Mulligan et al,19 reported a lack of C N P 
effect on the basal or stimulated A C T H release f rom 
equine pi tui tary cells in vitro, which suggests that 
C N P does not act at the pi tui tary to inhibit A C T H 
secretion. In contrast, Fink et al} have demonstrated 
a marked facilitatory effect of intra-atrial but not 
i.c.v. administration of a n t i - A N P serum on the 
A C T H response to stress and conclude that A N P 
acts at the level of pituitary. All these findings suggest 
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that A N P acts as a hormone on the pituitary, but 
C N P acts centrally. Furthermore, the concentration 
of C N P in the cerebrospinal fluid is one order of 
magnitude greater than that of ANP. 1 3 
In our experiments, C N P influenced the hormone 
responses brought about by ether, electric shock and 
restraint to different extents. It is clear from a number 
of experiments that different stressful stimuli activate 
the pituitary-adrenal system by different pathways. 
Ether may act directly on the medial basal hypo-
thalamus, because it can induce the activation of the 
pituitary-adrenal axis in spite of complete hypothal-
amic deafferentation.20"22 O n the other hand, electric 
shock and other painful stimuli, such as s.c. injection 
of capsaicin or traumatic stress, trigger A C T H release 
through sensory neural pathways: either cord section 
or denervation of the hind leg prevented A C T H 
release.23"25 
Other hormonal responses (oxytocin, vasopressin) 
also vary according to the type of stress.24,22 It appears 
that ether and other stressful stimuli activate the 
hypothalamo-pituitary stress axis by different routes, 
and that the hormonal responses that they produce 
are not the same. C N P could exert its inhibitory 
effects at a number of different central sites and so 
affect the secretion of various hormones differently. 
Conclusion 
These data demonstrate that C N P administered i.c.v. 
to rats is able to block ether-stress-induced activa-
tion of the pituitary-adrenal axis by a central action 
in vivo. However, it can only attenuate the response 
evoked by electric shock, and is even less effective 
in diminishing the restraint-induced corticosterone 
response. This discrepancy may be explained by 
differences in the anatomical or biochemical organi-
zation of the pathways involved in the various stress 
responses. 
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E L S E V I E R 
EFFECTS OF BRAIN NATRIURETIC PEPTIDE ON PITUITARY-ADRENAL ACTIVATION IN 
RATS 
Department of Pathophysiology, Albert Szent-Györgyi Medical University, MTA-SZOTE Neurohumoral 
Research Group, Semmelweis u. 1, POB 531, H-6701 Szeged, Hungary 
The aim of this study was to characterize the effects of brain natriuretic peptide (BNP) on the 
hypothalamo-pituitary-adrenal (HPA) responses to different stress paradigms (ether stress, 
electric shock and restraint). Rats were subjected to the stressful stimuli after 
intracerebro ventricular administration of BNP (32.5 ng - 6.5 pig) and plasma corticosterone 
was used as an indicator of the HP A activation. BNP did not modify the basal secretion, but 
inhibited the stress-induced rise in plasma corticosterone in a dose-dependent manner. BNP 
proved most effective in decreasing the corticosterone response to ether stress and attenuated 
the electric shock and restraint-induced HP A activation to a lesser extent These results 
confirm the view that BNP takes part in the regulation of the HPA system. 
Key Words: brain natriuretic peptide, pituitary-adrenal system, ether stress, restraint stress, electric shock 
Brain natriuretic peptide (BNP) is the second member of the natriuretic peptide family first isolated from 
porcine brain (1) and its concentration was shown 13 times higher than that of atrial natriuretic peptide (ANP) 
in the central nervous system (CNS) (2). BNP with 26 or 32 amino acid residues exhibits a marked sequence 
homology to (ANP) (1). Natriuretic, hypotensive and smooth muscle relaxant .activities of BNP seem to be 
very similar to those of ANP (1,3). Natriuretic peptides are distributed in discrete brain regions of different 
species (1,2,4-6) and take part in the regulation of hormone secretion (7-13), water drinking (14) and 
behaviour (15). Saper et al. (6) demonstrated that BNP is present in the CNS of the rat in a distribution, which 
is different from that of ANP. Moreover Brown et al. (16) localized high affinity binding sites for ANP and 
BNP in various brain regions of the rat such as area postrema and hypothalamic nuclei. Since other studies 
presented contradictory data (17,18), the reported effects of centrally administered BNP (11-15) in the rat 
may reflect either physiological or pharmacological action. Studies indicate that ANP can regulate, mainly as 
an inhibitor, the hypothalamo-pituitary-adrenal (HPA) axis at a pituitary (7,8) and hypothalamic levels (9,10). 
Former results propose that the HPA response to various stressful stimuli may involve different neural 
pathways. Ether presumably directly stimulates the medial basal hypothalamus, because it activates 
the pituitary-adrenal axis in spite of complete hypothalamic deafferentation (19,20). 
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Electric shock and other painful stimuli, trigger ACTH secretion through sensory neural pathways, 
because either cord section or denervation of the hind leg prevents the release of ACTH (21). 
Restraint represents the environmental or "psychological" stress paradigm, which evokes the stress 
reaction through the ventral amygdalofugal pathway and the central amygdaloid nucleus (22,23). 
Previous studies showed that not only ACTH but oxytocin or vasopressin responses induced by 
restraint or ether also vary according to the applied stress paradigm (24,25). Furthermore, our previous 
finding? (26) showed that C-type natriuretic peptide (CNP) abolished the corticosterone response evoked by 
ether stress, but caused only less marked inhibition of die HPA response brought about by restraint and electric 
shock As previous reports examined the action of BNP only on the basal (12) and endothelin-induced HPA 
activation (11), in the present study we have investigated the in vivo effects of intracerebroventricularly (i.c.v.) 
administered BNP on HPA responses to ether stress, electric shock and restraint to clarify whether this peptide 
shows any challenge specific action similar to that of CNP (26). 
Methods 
" Animals and Surgery 
The animals were kept and handled during the experiments in accordance with the instructions of the Albert 
Szent-Gyorgyi Medical University Ethical Committee for the Protection of Animals in Research. Male Wistar 
rats weighing 150-200 g upon arrival were, used. The animals were kept in their home-cages at a constant 
room temperature on a standard illumination schedule with 12-h light and 12-h dark periods (lights on from 
6.00 am.). Commercial food and tap water were available ad libitum. The animals were allowed a minimum 
of 1 week to acclimatize before surgery. In order to minimize the effects of nonspecific stress the rats were 
handled daily. The rats woe implanted with a stainless steel 20G1.5 Luer cannula (10 mm long) aimed at the 
right lateral cerebral ventricle under Nembutal (35 mg/kg, intraperitoneal) anesthesia. The stereotaxic 
coordinates woe 0.2 mm posterior; 1.7 mm lateral to the bregma;' 3.7 mm deep from the dural surface, 
according to the atlas of Pellegrino et al. (27). Cannulas were secured to the skull with dental cement and 
acrylate. After decapitation in order to verify the correct positioning and the permeability of the cannulas, 
methylene blue was injected into each decapitated head and the brains were dissected. Results from animals 
with incorrectly positioned cannulas were excluded from the statistical evaluation. 
Peptide administration 
The rats were used after a recovery period of at least 5 days. All experiments were carried out between 8.00 
and 10.00 am. In order to obtain more comparable data, the applied doses of BNP (from 32.5 ng to 6.5 pg) 
were equimolar to.the CNP concentrations used in our previous experiments (26). BNP was dissolved in 
saline, and was injected i.c.v. in a volume of 2 pi to conscious, freely-moving rats. The control animals 
received the same volume of saline. 
Stress procedures 
Thirty minutes after the peptide administration, the animals were subjected to one of the following stimuli: 
ether stress, electric foot-shock and restraint For ether stress, the animal was placed for 1.5 min in a jar 
containing an ether-dampened paper at the bottom. Unconsciousness always occurred within this period of 
breathing the ether-saturated atmosphere. In the case of the electric shock, the rats were placed in a shock-box 
(a wooden box with a stainless steel grid floor) and exposed to unescapable shocks. Electric foot-shocks (1 
mA AC., 50 Hz) were delivered to the paws by a shocker (Master Shocker, Lafayette Instrument Co., USA) 
using direct output. The current was turned on for 5 sec, then off for 10 sec for a period of 1 min. For the 
restraint procedure, the animals were placed for 30 min in a 20 cm long, 6 cm wide non-transparent plastic 
tube, which was dosed at either end with a 2 cm wide metal plate allowing air supply from both ends. 
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Corticosterone assay 
The rats were decapitated 30 min after the stress procedures and approximately 3 ml trunk blood was 
collected in heparinized tubes. The plasma corticosterone level was determined by the fluorescence assay 
described by Zenker and Berstein (28), as modified by Purves and Sirett (29). 
Reagents and Drugs 
During the experiments, the following substances were used: diethyl ether, methylene chloride and sulfuric 
acid of analytical grade (Reanal, Budapest), and porcine BNP (PBNP32) (Bachem, Germany). 
Statistical analysis 
All data are given as means ± S.E.M Statistical analysis of the results was performed by one-way ANOVA 
followed by Tukey's post hoc comparison test A probability level of 0.05 was accepted as indicating a 
statistically significant difference. 
Results 
BNP in the doses applied (0.0325, 0.325, 3.25 or 6.5 pg) did not influence the basal corticosterone secretion 
(Figs. 1-3.). Ether stress (Fig. 1.), electric shock (Fig. 2.) and restraint (Fig. 3.) all increased the plasma 
corticosterone concentration approximately 4-fold. 
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The effect of brain natriuretic peptide on the plasma corticosterone levels evoked by ether 
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The effect of brain natriuretic peptide on the electric shock-induced increase in plasma 
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The effect of brain natriuretic peptide on the plasma corticosterone level induced by restraint. 
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BNP caused a dose-dependent decrease in the ether stress-induced corticosterone response (Fig. 1.). The 
highest dose of BNP (6.5 pg) inhibited the corticosterone response by 42.8% and this effect proved highly 
significant (F (9, 84) = 110.13, p < 0.005). Even in . a dose of 0.325 pg, BNP decreased the plasma 
corticosterone level to a statistically significant extent as compared to the stressed animals (p < 0.05). 
The 6.5 pg dose of BNP reduced the corticosterone response to electric shock (Fig. 2.) by 35.7% (F (7,63) = 
70.2, p < 0.005) and the dose of 3.25 pg likewise elicited significant inhibition (p < 0.01). However, the dose 
of0.325 pg, which proved effective in the case of ether stress, Med to produce a significant inhibition (p = 
0.99). 
The effect of BNP on the corticosterone response to restraint (Fig. 3.) was less marked. Only the highest dose 
of BNP (6.5 pg) was able to attenuate (by 28.8%) the restraint-induced increase in plasma corticosterone 
level to a statistically significant extent (F (5,41) = 60.4, p < 0.005). 
Discussion 
Previous findings showed that ANP and BNP share biological activity in extracerebral tissues (1,3) and the 
central effects of BNP on vasopressin secretion (13), water-drinking (14) and learning behaviour (15) are 
quite similar to those of ANP. Other results demonstrated that ANP decreased hypothalamic CRF release 
(9,10). However several investigators demonstrated that ANP inhibited the HPA system preferentially at a 
pituitary level (7,8). 
The present data have dearly shown that centrally administered pBNP32 does not affect the basal release of 
corticosterone, but dose-dependently inhibits the hormonal response to three stressful stimuli in vivo. The 
action site of i.c.v. administered BNP on the stress response is not established. However we have strong 
evidence that high density binding sites for BNP exists in the subfornical organ, supraoptic and paraventricular 
nudei (16), which structures regulate pituitary ACTH secretion. This inhibitory effect of BNP on the HPA 
axis is very probably mediated by cyclic guanosine monophosphate (cGMP) (30), and previous studies 
(31,32) demonstrated that cGMP-dependent protein-kinases might play an important role in the action of 
BNP on the HPA system.. 
Nevertheless our previous results (26) revealed that the effect of CNP is more marked and more stressor-
specific than that of BNP. These findings can be explained by the different distributions of natriuretic peptides 
(5,6,16-18) and their receptors (33,34) in the CNS, and by the feet that ANP and BNP prefer the A-type 
(NPR-A), while CNP the B-type (NPR-B) natriuretic peptide receptor (35). High NPR-B expression can be 
observed in all the structures (preoptic-hypothalamic structures, amygdala, brainstem) (34) that take part in 
the organization of the anatomical pathways of the applied stressors (ether, restraint, dectric shock). However 
BNP binding (16) is practically restricted to the subfornical organ, supraoptic and paraventricular nuclei, 
which can explain the fact that the action of BNP is less dependent on the type of the applied stress paradigm 
than that of CNP. Despite the different distribution of endogenous sources of ANP and BNP (6) these 
structurally related peptides possibly have an impact on the common pathway of the stress response either at a 
hypothalamic or at a pituitary level (7-11), while CNP as the most abundant natriuretic peptide in the CNS (5) 
may inhibit the ascending stress-pathways to a different extent 
The results provide evidence for an inhibitory modulation of BNP on the activated HPA system. We conclude 
that BNP does not influence the basal corticosterone secretion, but in a dose-dependent manner diminishes 
the corticosterone response to ether stress, electric shock and restraint. Thus, the present publication, together 
with our previous results (26), strongly support the hypothesis that natriuretric peptides may play an important 
role in the regulation of stress response. 
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Effects of Orexins on the Hypothalamic-Pituitary-Adrenal System 
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Abstract 
The effects of the recently identified neuropeptides orexin-A and orexin-B on the hypothalamic-
pituitary-adrenal (HPA) system were investigated. An in vivo system was used to assess the central 
effects of both orexin-A and orexin-B. Different doses of the orexins (2.8-560 pmol) were 
administered intracerebroventricularly (i.c.v.) to adult male rats, and plasma corticosterone was used 
as an index of the degree of the activation of the HPA system. Both peptides exhibited a clear dose-
response action, although orexin-B proved to be less effective than orexin-A. Pretreatment with the 
corticotropin-releasing hormone (CRH) antagonist a-helical CRH 9 _ 4 1 completely prevented the action 
of the orexins. Orexin-A, orexin-B or adrenocorticotropic hormone (ACTH) was further administered 
intraperitoneaily (i.p.). While ACTH evoked a significant adrenal response, the orexins did not 
influence the basal secretion. Adrenal slices, oxygenized and perifused with Krebs' solution, were 
also treated with orexin-A, orexin-B or ACTH. Both orexins failed to modify the release of 
corticosterone, but ACTH induced a marked adrenal response. This study suggests that these 
appetite-regulating peptides might activate the HPA system at a central level but neither orexin-A nor 
orexin-B appears to modulate directly the adrenal corticosterone release. 
The hypothalamus plays a central, integrative role in the 
control of neuroendocrine, autonomic and energy home-
ostasis. Fasting evokes a complex response of the hypotha-
lamic-pituitary-adrenal (HPA) system, altering both the basal 
function and the responsivity to stressors. The rhythm in HPA 
activity follows the rhythm in food consumption (1, 2). 
Insulin-induced acute hypoglycemia, which is a potent 
activator of the HPA axis, reflects the strong functional 
relationship between the hypothalamic feeding centres and the 
HPA system (3, 4). Neuropeptides such as corticotropin-
releasing hormone (CRH), melanin concentrating hormone 
(MCH) and neuropeptide Y (NPY) have been found to be 
important regulators of both the HPA system and feeding 
behaviour (5-9). 
Two novel neuropeptides, orexin-A and orexin-B, have 
been identified as mediators of homeostatic and endocrine 
hypothalamic functions (10-13). Both are processed from a 
130-amino acid precursor, prepro-orexin and they differ 
markedly in structure and function (10). These two neuropep-
tides and their receptors display a specific tissue distribution, 
which resembles that of MCH (9). Prepro-orexin mRNA 
activity is abundantly expressed in the lateral hypothalamus 
(10, 14), and Nambu et al. (15), using an antiorexin serum, 
demonstrated the same distribution pattern of the orexin-
immunoreactive neurones. Although most of these neurones 
are located in the hypothalamus, a dense projection of orexin-
positive nerve terminals is found in both hypothalamic and 
extrahypothalamic structures (15, 16). Because orexins are 
synthesized in the lateral hypothalamus (10, 14) [an area 
classically regarded as the feeding centre (17)] and enhance 
food intake (10, 18), and because the vast majority of orexin 
neurones express leptin receptors (19), these neuropeptides 
seem to be among the central regulators of feeding. 
The integrated action of the paraventricular nucleus (PVN) 
and the arcuate nucleus appears to play a crucial role in the 
regulation of both stress response (5, 20) and feeding 
behaviour (9) through the secretion of neuropeptides such 
as CRH and NPY (5-7, 9, 21). Recent studies have 
demonstrated that insulin-induced acute hypoglycemia, a 
well-established stress paradigm (3,4), can activate the orexin-
containing cells in the lateral hypothalamus (22,23). Although 
orexin-containing neurones have not yet been detected in the 
PVN and the arcuate nucleus, neuronal projections from the 
lateral hypothalamus to the PVN have been identified (11,15, 
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24). Histological studies have verified the functional activation 
of these neuronal circuits: i.c.v. infusion of orexins greatly 
increased the expression of c-fos, a marker of neuronal 
activation, in the PVN and the arcuate nucleus (18, 24). 
Moreover, van den Pol et al. (25) reported that orexins 
increase the synaptic activity of hypothalamic neuroendocrine 
cells. 
The anatomical and functional connections between the 
orexin neurones of the lateral hypothalamus and the PVN-
arcuate nucleus complex support the hypothesis that orexin 
neurones can mediate a complex endocrine and homeostatic 
response to fasting and insulin-induced hypoglycemia. The 
present experiments were designed to test the effects of both 
orexin-A and orexin-B on the HPA system and to investigate 
the sites mediating their action. The orexins were administered 
i.c.v. in an attempt to characterize their central effect. Rats 
were pretreated with CRH antagonist a-helical CRH9_4I to 
elucidate whether these peptides activate directly the pituitary 
adrenocorticotropic hormone (ACTH) secretion or through 
the stimulation of hypothalamic CRH release. Intraperitoneal 
administration of the peptides and an in vitro system of 
perifused adrenal slices were used to investigate the peripheral 
action of the orexins. 
Materials and methods 
Animals 
The animals were kept and handled during the experiments in accordance with 
the instructions of the University of Szeged Ethical Committee for the 
Protection of Animals in Research. Male Wistar rats weighing 130-200 g upon 
arrival were used. The rats were kept in their home-cages at a constant room 
temperature on a standard illumination schedule with 12-h light and 12-h dark 
periods (lights on from 06.00 h). Commercial food and tap water were 
available ad libitum. The rats were allowed a minimum of 1 week to acclimatize 
before surgery, and to minimize the effects of nonspecific stress the rats were 
handled daily. 
Experimental protocols 
In vivo experiments 
To clarify the central and peripheral effects of the orexins, we used both i.c.v. 
and i.p. peptide administration. In the case of i.c.v. administration (experiment 
I, experiment 2), the rats were implanted with a stainless steel 20-gauge 1.3 
Luer cannula (10 mm long) aimed at the right lateral cerebral ventricle under 
Nembutal (33 mg/kg i.p.) anaesthesia. The stereotaxic coordinates were 
0.2 mm posterior; 1.7 mm lateral to bregma; 3.7 mm deep from the dural 
surface, according to the atlas of Pellegrino et al. (26). Cannulae were secured 
to the skull with dental cement and acrylate. The rats were used after a 
recovery period of at least 3 days. All experiments were carried out between 
08.00 h and 10.00 h. Peptides, dissolved in saline, or saline alone (control 
animals) were injected i.c.v. to conscious rats with Hamilton microsyringe over 
30 s in a volume of 2 pi, immobilization of the rats being avoided during 
handling. In order to obtain comparable data, we used equimolar doses of 
orexin-A, orexin-B or ¿-helical CRF9_41. For peripheral administration 
(experiment 3), equimolar doses of orexins or ACTH were dissolved in 0.5 ml 
saline and injected i.p. Control animals received 0.5 ml saline i.p. In order to 
obtain trunk blood for corticosterone assay, in every experiment the rats were 
sacriliced by decapitation and approximately 3 ml blood was collected in 
heparinizcd tubes. In the case of i.c.v. administration, methylene blue was 
injectcd into each decapitated head and the brains were dissected to verify the 
correct positioning and the permeability of the cannulae. Only data from rats 
with accurate placement were considered for the statistical evaluation. 
Experiment 1: Rats received different i.c.v. doses of either orexin-A (from 
2.8-280 pmol) or orexin-B (from 28-560 pmol). The doses of the orexins were 
selected with a view to finding the minimal statistically effective concentration 
and identifying the concentration evoking the maximal response. Control rats 
received saline alone. Each rat was returned to its home cage and maintained in 
a nonstressful environment till they were decapitated 30 min after the i.c.v. 
injection. 
Experiment 2: For this experimental setting, we selected the most effective 
doses of the orexins (140 pmol and 280 pmol for orexin-A and orexin-B, 
respectively), and animals were divided into four treatment groups. Thirty min 
before orexin administration, group II and IV received an equimolar dose of x-
helical CRF9_4 | i.c.v., and group I and III received saline alone. Afterwards, 
group III and IV were treated with orexin, while vehicle was injected to groups 
I and II. The rats were killed 30 min after the second treatment. 
Experiment 3: In this study, rats received an equimolar dose of orexin-A, 
orexin-B or ACTH (280 pmol) i.p. Saline was injected i.p. into the controls. 
Trunk blood was collected 30 min later for corticosterone assay. 
In vitro experiments 
We used the in vitro system described by Saffran and Schally (27) as a starting-
point in developing our experimental design. Rats weighing 200-230 g were 
decapitated and the adrenals were removed and cleaned from the adhering fat 
and capsule with fine surgical forceps and a blade. The adrenals were weighed 
on a micro torsion balance (fresh wet weight approximately 12-16 mg) and 
each pair was immediately transferred to a separate Petri dish containing ice-
cold, Krebs' solution (113 mM NaCI, 4.7 mM KC1, 1.2 mM MgS04, 25 mM 
NaHCOj, 11.3 mM glucose, 1.2 mM KH2P04, 2.5 mM CaCU, pH = 7.4) as 
incubation medium. The adrenals were rapidly, and as evenly as possible, cut 
into approximately 500 pm slices with a surgical blade. The slices from each 
pair were placed in a separate glass flask. The flasks, containing 3 ml 
incubation medium, were submerged in a water-bath at 38°C and constantly 
and gently gassed through a single-use needle (30-gauge; 0.3 x 13) with a 
mixture of 3% C0 2 and 93% 0 2 ; the pH was maintained at 7.4. The adrenals 
were preincubated for 1 h, at the end of which the medium was sucked out and 
discarded. In 5 ml of fresh medium, different doses of orexin-A, orexin-B or 
ACTH (or the medium alone as a control) were added to the adrenals. The 
samples were incubated for 30 min, after which 200 pi aliquots of the medium 
were transferred to centrifuge tubes for corticosterone assay. 
Corticosterone assay 
The plasma corticosterone concentration was determined by the fluorescence 
assay described by Zenker and Bernstein (28), as modified by Purves and Sirett 
(29). In the in vivo experiments, corticosterone concentration was expressed as 
pg/100 ml. In the in vitro experiments, the amount of corticosterone secreted 
was expressed in terms of 100 mg adrenal tissue, for a period of 1 h 
(pg/100 mg/h). 
Reagents and drttgs 
For the experiments, the following substances were used: ethyl alcohol, 
methylene chloride and sulphuric acid of analytical grade (Reanal, Budapest) 
for the corticosterone assay; and NaCI, KC1, MgS04, NaHC03, KH2P04, 
CaCl2 and glucose (Reanal, Budapest) for the Krebs' buffer preparation. The 
peptides applied were rat orexin-A, rat orexin-B (both from Bachem, 
Switzerland), ACTH (/l'"24 corticotropin, Ciba-Geigy, Vienna) and x-helical 
CRH9_41 (Bachem). 
Statistical analysis 
All data are given as means+SEM Statistical analysis of the results was 
performed by one-way ANOVA followed by Tukey's post hoc comparison test. A 
probability level of 0.05 was accepted as statistically significant. 
Results 
In vivo experiments 
Study 1: Effects of orexin-A and orexin-B administered i.c.v. 
on basal corticosterone release 
Orexin-A increased corticosterone secretion in a dose-
dependent manner (Fig. 1). The most effective dose 
(140 pmol) elevated the plasma concentration of corticoster-
one by 208% compared to the control (F8.X8=4.62; P < 0.001). 
A higher dose of orexin-A (280 pmol) proved less effective, 
evoking only a 149% increase (P<0.05) vs the control. 
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Study 3: Comparison of effects of i.p. administered orexins 
and ACTH on basal corticosterone release 
The basal plasma concentration of corticosterone 
(15 + 1.61 pg/100 ml) was not modified by exposure to either 
orexin-A (280 pmol: 14.1 ±2.11 pg/100 ml) or orexin-B 
(280 pmol: 18.9 ±3 .46 pg/100 ml). By contrast, an equimolar 
dose of ACTH elicited 127% increase (34.05±5.1 pg/100 ml; 
F3,i6 = 7-61, P < 0 . 0 1 vi control; n = 5 in all cases). 
In vitro experiments 
The basal secretion of corticosterone from isolated adrenals in 
vitro (3.2 + 0.8 pg/100 mg/h) was not significantly influenced 
by exposure to orexin-A (280 pmol: 2.7 ± 0 4 pg/100 mg/h; 
2.8 nmol: 3.3 ± 0 9 pg/100 mg/h) or by exposure to orexin-B 
(280 pmol: 2.5 ± 0 5 pg/100 mg/h; 2.8 nmol: 5.3 ± 2 . 3 pg/100 
mg/h). Exposure to ACTH (280 pmol) produced the expected 
significant increase in secretion (13 ±4 .3 pg/100 mg/h; 
F 5 i 2 4 = 3.78, P < 0 . 0 5 v i control; n = 5 in all cases). 
Orexin-B likewise caused a dose-dependent increase 
(Fig. 1). However, it peaked at a dose of 280 pmol and 
resulted in only a 189% increase above control levels 
(P<0.005). 
Study 2: Effects of a-helical C R H 9 _ 4 , on H P A activation 
evoked by orexins 
The CRH antagonist a-helical C R H 9 _ 4 1 completely abolished 
the corticosterone response evoked by 140 pmol orexin-A 
(F5 .6 5= 12.38; P < 0.005 vi 140 pmol orexin-A) (Fig. 2). The 
response induced by orexin-B was similarly inhibited by a -
helical C R H 9 _ 4 1 (PcO.OOl vi 280 pmol orexin-B) (Fig. 2). 
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Discussion 
Previous studies have demonstrated that the orexins posses 
prominent neuroendocrine effects. Pu et al. (12) observed that 
both orexin-A and -B stimulated luteinizing hormone 
secretion. Hagan et al. (13) showed that i.c.v. applied 
orexin-A inhibited prolactin and growth hormone release 
and evoked a dose-dependent corticosterone secretion. The 
present experiments were designed to extend our under-
standing of the role of both orexin-A and -B in the regulation 
of the HPA system. We attempted to identify the site of action 
of the orexins and compared the effects of these related 
peptides, which are quite distinct in their chemical nature and 
differ in their physiological actions (10, 18, 30, 31). Orexin-A, 
i.c.v., elicited a dose-dependent increase in corticosterone 
release, in agreement with the findings of Hagan et al. (13). 
Orexin-B administered i.c.v. also activated the HPA system in 
a dose-dependent manner. However, it is noteworthy that 
orexin-B was less effective than orexin-A. Orexin-A is a 
33-amino acid residue peptide with two intrachain disulphide 
bonds; and both termini of the peptide are blocked post-
translationally. In contrast, orexin-B, a 28-residue linear 
peptide with a free A-terminus, appears more susceptible to 
inactivating peptidases (31). These two peptides can activate 
two distinct G-protein-coupled cell surface receptors, orexini 
and orexin2. Both orexin-A and orexin-B have high affinities 
for orexin2, suggesting that it is a nonselective orexin receptor. 
In contrast, orexini is selective for orexin-A, binding orexin-B 
with an affinity three orders of magnitude lower (10). Previous 
studies have demonstrated that the effect of orexin-A on 
nutritional homeostasis (10, 18) is more potent and longer-
lasting than those of orexin-B. Furthermore, the effect of 
orexin-B on behavioural phenomena appears to be consider-
ably different from orexin-A (30). 
Both peptides furnish dose-response curves, with a down-
turn phase. This resembles the action of orexin-A on feeding 
(18), and the bell-shaped dose-response curve of the food 
intake-stimulating effect of NPY (32), and presumably reflects 
7 2000 Blackwell Science Ltd. Journal of Neuroendocrinology. 12. 1174-1178 
functional antagonism in postreceptorial signal transduction 
(33). 
To investigate whether orexins evoke the activation of the 
HPA system at a hypothalamic or at a pituitary level, rats 
were pretreated i.c.v. with the CRH antagonist a-helical 
CRH9_4 | . The actions of the most effective dose of both 
orexin-A and orexin-B could be completely abolished by the 
preliminary administration of a-helical CRH9_4i . These 
results, and the fact that the amino acid sequences of the 
orexins exhibit little similarity to the sequences of any other 
peptides (5, 10), suggest that orexins might not act on the 
pituitary CRH receptors, but rather bring about hypotha-
lamic CRH secretion. These data are in accordance with the 
anatomical findings. Nambu et al. (15) reported that the 
anterior and intermediate lobes of the pituitary do not contain 
orexin-positive fibres. Besides, the complete inhibition of the 
stimulatory action of orexins by the application of CRH 
antagonist a-helical CRH 9 _ 4 | implies that vasopressin 
mediation might not play a major role in the orexin induced 
HPA activation. 
Further studies were undertaken to investigate whether 
orexins influence the function of the peripheral part of the 
HPA system. The present data clearly demonstrate that 
neither orexin-A nor orexin-B has a direct impact on the basal 
corticosterone release of the adrenal gland. Orexins adminis-
tered i.p. failed to influence the basal glucocorticoid release, 
whereas ACTH elicited a significant response. We also used an 
in vitro adrenal perifusion system to ensure that these peptides 
did in fact reach the adrenal glands. Kastin et al. (31) recently 
demonstrated that orexin-A but not orexin-B crosses the 
blood-brain barrier, and this in vitro system provided a 
completely separate examination of adrenal function. There-
fore, in this experimental setting, centrally mediated actions of 
orexins could be excluded. However, even though different 
doses of the peptides were applied, we could not demonstrate 
any effects of the orexins on corticosterone secretion. These 
findings are in accordance with the results of recent 
histological studies, which reported that these novel neuro-
peptides are practically confined to the central nervous system 
(10). 
Our results, taken together with previous findings (9, 13, 
30), support the concept that the orexins participate in the 
regulation of the PVN and the arcuate nucleus, activating the 
cells of these nuclei through synaptic contacts, or act as 
neurohormones, being discharged into the ventricular circula-
tion (34). Griffond (23) proposed that the orexin neurones 
may belong to the glucose-sensitive neurones of the lateral 
hypothalamus (17), and might play important roles in the 
hypoglycaemia-induced endocrine and behavioural responses. 
The stimulatory action of orexin-A on grooming behaviour 
provides further evidence for the hypothesis that orexin 
neurones control the physiological functions of the PVN (30). 
The well-established mediator of these processes is CRH; 
when released from the PVN, this increases grooming (35), or 
when it reaches the anterior pituitary through the median 
eminence, it activates ACTH secretion (5). Furthermore, 
orexin-induced CRH and glucocorticoid secretion appear to 
regulate appetite (9). CRH decreases food intake (21, 36), 
raising the possibility that it functions as a negative feed-back 
regulator (9), while adrenal glucocorticoids seem to modulate 
Effects of orexins on the HPA system 1177 
the output of orexigenic and anorexigenic signals (9) and, as 
catabolic hormones, cause the mobilization of energy stores. 
It has not yét been clarified whether the orexin containing 
cells act directly on the CRH-positive cells of the PVN or 
through the activation of other hypothalamic neurones. 
Several lines of evidence suggest that the orexin, NPY and 
CRH neurones interact in the hypothalamus, integrating the 
functions of the HPA axis and the hypothalamic feeding 
system (6, 7, 11). Further studies are required to elucidate the 
function and interaction of these neuropeptides in the 
regulation of the HPA system. 
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Abstract 
The role of neuropeptide Y (NPY) in the mediation of orexin-induced hypothalamic-pituitary-adrenal 
(HPA) activation was investigated in the rat. The HPA system was stimulated by 
intracerebroventricular (i.c.v.) administration of orexin-A or orexin-B (140 or 280 pmol, respectively) , 
and the plasma concentration of corticosterone was used as an index of the degree of activation, 
i.c.v. pretreatment with NPY antagonist or NPY antiserum (30 min or 24 h before orexin 
administration, respectively) inhibited the orexin-induced corticosterone release. The inhibitory actions 
of the antagonist and the antiserum were revealed by the dose-response curve; the highest 
concentrations practically abolished the HPA activation evoked by the orexins. These data suggest 
that the HPA system-stimulating effect of the orexins may be mediated by NPY. 
Recent studies have demonstrated that the members of a novel 
family of neuropeptides, the orexins (1), can activate the 
hypothalamic-pituitary-adrenal (HPA) system (2-4) through 
the release of corticotropin releasing hormone (CRH). The 
orexin immunoreactive neurones are located in the lateral 
hypothalamus (1, 5), a structure described as the feeding 
centre (6), and orexins stimulate food intake (1,7). However, 
despite the specific and rather limited distribution of orexin 
neurones in the central nervous system (CNS) (1,5), orexin-A 
and orexin-B have impacts on numerous behavioural, 
endocrine and autonomic processes (1, 2, 8, 9). The dense 
projection of orexin neurones to other hypothalamic and 
extrahypothalamic structures (10, 11), and the widespread 
distribution of orexin receptors in the CNS (1, 12) appear to 
form the anatomical basis of such diverse actions. Never-
theless, the characteristic distribution of orexin neurones (1,5) 
raises the possibility that the orexins do not activate or inhibit 
CNS processes directly, but rather through the release of 
other neuropeptides. The effects of orexins on feeding (1) and 
hormone secretion (2-4, 9) markedly resemble those of NPY 
(13-18) and recent studies (19, 20), involving the use of NPY 
antagonist, have revealed that the hyperphagia elicited by 
orexins is at least partially mediated by NPY. Orexin axons 
synapse on the NPY cells in the arcuate nucleus, a nucleus 
regarded as one of the most important regulators of feeding 
(10, 21). Because the NPY-positive neurone population of the 
arcuate nucleus also plays a considerable role in the regula-
tion of the HPA system through the activation of the CRH 
neurones in the paraventricular nucleus (PVN) (14,17,22-25), 
it seemed worthwhile to investigate whether the NPY 
neurones are involved in the action of the orexins on the 
HPA system. By means of i.c.v. pretreatment with an NPY 
antagonist [a full sequence peptide (D-Trp32)-NPY, which 
proved to be highly specific inhibitor of hypothalamic actions 
of NPY both in vitro and in vivo (26)] or NPY antiserum, we 
aimed to elucidate the possible role of NPY in orexin-A and 
orexin-B-induced HPA activation. 
Materials and methods 
Animals 
Rats were kept and handled during the experiments in accordance with the 
instructions of the University of Szeged Ethical Committee for the Protection 
of Animals in Research. Male Wistar rats weighing 150-200 g were used. The 
rats were kept in their home cages at a constant room temperature under 
controlled lighting conditions (12:12 h light: dark cycle; lights on at 06.00 h). 
Commercial food and tap water were available ad lihiium. The rats were 
allowed a minimum of I week to acclimatize before surgery, and to minimize 
the clTects of nonspecific stress the rats were handled daily. 
To allow i.c.v. peptide administration, the rats were implanted with a 10-mm 
long stainless steel cannula (prepared from hypodermic Luer needle of 20-G 
x 1.5 inch) aimed at the right lateral cerebral ventricle under Nembutal 
(35 mg/kg. i.p.) anaesthesia. The stereotaxic coordinates were 0.2 mm poster-
ior; 1.7 mm lateral to the Bregma; 3.7 mm deep from the dural surface. 
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according to the atlas of Pellegrino et al. (27). Cannulae were secured to the 
skull with dental cement and acrylate. The rats were used after a recovery 
period of at least 5 days. All experiments were carried out between 08.00 h and 
10.00 h. Orexin-A or orexin-B dissolved in saline, or saline alone (control 
animals), was injected i.c.v. to conscious rats with a Hamilton microsyringe 
over 30 s in a volume of 2 pi. immobilization of the rats being avoided during 
handling. The doses of orexins applied were the concentrations that had 
proved the most effective in our previous experiments (4). To scrutinize the 
mediation of the action of the orexins. different dilutions of (D-Trp'h-NPY 
(26), as an NPY antagonist or NPY antiserum were applied i.c.v. (30 min or 
24 h before orexin treatment, respectively). The time intervals for antagonist 
and antiserum administration were chosen on the basis of previous data 
obtained with other antagonists and antisera (28). The doses of the antagonist 
and the antiserum were selected with a view to finding the minimal and 
maximal statistically effective concentrations. To obtain trunk blood for 
corticosterone assay, in both experiments, rats were killed by decapitation and 
approximately 3 mi blood was collected in heparinized tubes. Methylene blue 
was next injected into each decapitated head and the brains were dissected to 
verify the correct positioning and the permeability of the cannulae. Only data 
from rats with accurate placement were considered in the statistical evaluation. 
Corticosterone assay 
Plasma concentrations of corticosterone were determined by the fluores-
cence assay described by Zenker and Bernstein (29) as modified by Purves 
and Sirett (30). 
Statistical analysis 
All data are given as means+ SEM. Statistical analysis of the results was 
performed by one-way anova, followed by Tukey's post-hoc comparison test 
for unequal cell size. P<0.05 was considered statistically significant. 
Reagents and drugs 
For the corticosterone assay, the following substances were used: ethyl alcohol, 
methylene chloride and sulphuric acid of analytical grade (Reanal. Budapest). 
The peptides applied were rat orexin-A, rat orexin-B, (D-Trp32)-NPY 
(Bachem. Switzerland) and NPY antiserum (Yanaihara Institute Inc., Japan). 
Results 
Study 1: Effects of NPY antagonist on HPA activation 
evoked by orexins 
Rats were divided into four treatment groups. Thirty minutes 
before orexin administration, groups II and IV received 
different concentrations of (D-Trp3 2)-NPY (from 280 pmol to 
560 pmol) i.c.v., whereas group I and III received saline alone. 
Groups III and IV subsequently received equimolar doses of 
orexin-A or orexin-B (140 or 280 pmol, respectively) i.c.v., 
while groups I and II received saline alone. Each rat was 
returned to its home cage and maintained in a nonstressful 
environment until it was decapitated 30 min after the second 
i.c.v. injection. Both orexin-A and orexin-B elicited a pro-
nounced increase in the plasma concentration of cortico-
sterone relative to the control (121% and 98%, respectively), 
the effect proving statistically significant [F(l 1,181) = 7.01, 
P <0.001 and P < 0.001, respectively, versus the control)]. 
(D-Trp j2)-NPY pretreatment diminished the orexin-induced 
corticosterone response in a dose-dependent manner. The 
doses of 280 pmol and 420 pmol revealed a tendency to 
attenuation, but only the highest dose (560 pmol) brought 
about a statistically significant inhibition (P<0.05 versus 
140 pmol orexin-A and 280 pmol orexin-B). diminishing the 
orexin-A or orexin-B-induced HPA activation by 42% and 
46%, respectively (Fig. 1). 
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Study 2: Effects of NPY antiserum on orexin-induced HPA 
activation 
Different dilutions of NPY antibody (groups II and IV) 
or normal rabbit serum (groups I and III) were injected i.c.v. 
24 h before orexin administration. The rats were further 
treated with either orexin-A (140 pmol) or orexin-B (280 pmol) 
(groups III and IV), while vehicle was injected in groups I and 
II. The rats were killed 30 min later, as above. NPY antiserum 
dose-dependently inhibited the corticosterone response eli-
cited by the orexins. Even a dilution of 1 :20 resulted in a 
marked inhibition of the orexin-A and orexin-B-evoked HPA 
activation (27% and 40% decrease, respectively), but only a 
dilution of 1: 10 caused a statistically significant inhibition of 
the HPA response evoked by orexin-A [56%, F(11.129) = 7.41 
P<0.05 versus 140 pmol orexin-A] or orexin-B (51%, P<0.01 
versus 280 pmol orexin-B) (Fig. 2). 
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Fig. 1. Effects of neuropeptide Y (NPY) antagonist on corticosterone 
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Discussion 
The present experiments were designed to elucidate the 
mediation of the action of the orexins on the HPA system, 
and to clarify the function of NPY in this process. 
Pretreatment with NPY receptor antagonist (D-Trp32)-NPY 
(26) dose-dependently inhibited the orexin-induced HPA 
activation, although only the highest concentration of the 
antagonist resulted in a pronounced attenuation of cortico-
sterone release. Balasubramaniam et al. demontrated that 
(D-Trp32)-NPY shows high affinity and specificity to the 
hypothalamic NPY receptors and competitively blocks the 
in vitro (adenylate cyclase inhibition on hypothalamic 
membranes) and in vivo (stimulation of feeding) actions 
of NPY (26). However, a recent study raised the possibility 
that NPY can act through the orexin receptors (31), there-
fore to strenghten our results NPY antiserum was used to 
neutralize the peptide. The antiserum, which has a 100% 
specificity to human/rat NPY, brought about a highly 
significant inhibition of the action of the orexins and a 
1:10 dilution of the antiserum appeared to neutralize the 
releasable pool of NPY entirely. 
Our results further support histological data that the orexin 
neurones, projecting from the lateral hypothalamus, relay the 
impulses from the feeding centre of the lateral hypothalamus 
to the HPA system: orexin-positive nerve terminals can be 
demonstrated on the NPY neurones of the arcuate nucleus 
(10, 21), and abundant NPY-positive projections from the 
arcuate nucleus to the PVN have been verified (21, 24,25, 32). 
Moreover, immunocytochemical studies have documented the 
presence of NPY perikarya in the PVN too, and a close 
apposition of orexin-positive fibres to the paraventricular 
NPY neurone population (21). The histological data and our 
present findings suggest that (i) the hypoglycaemia-activated 
orexin neurones (33) presumably give rise to NPY secretion in 
the arcuate nucleus and/or the PVN and (ii) the released NPY 
stimulates the paraventricular CRH neurones and conse-
quently activates the HPA axis (17). CRH may act as a 
feedback regulator of appetite (34), while the glucocorticoids 
play a permissive role in the central regulation of feeding (35) 
and elicit the characteristic catabolic processes of starvation. 
The results obtained in the present study clearly reflect that 
NPY mediation plays an exclusive role in the transmission of 
orexin signalling to the HPA system because both the NPY 
antagonist and the NPY antiserum, in the highest concentra-
tions, almost completely blocked the corticosterone release 
evoked by the orexins. 
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